Swiss pharmaceutical giant Novartis has continued the strong pace of growth of recent quarters in the first three months of 2025. Contrary to the expectations of many analysts, the company has raised its outlook again, for the ninth quarter in a row. +Get the most important news from Switzerland in your inbox Between January and March, Novartis generated sales of $13.2 billion (CHF10.9 billion). This is an increase of 12% compared to the same period last year, the Group announced on Tuesday. At constant exchange rates (CER), the increase was 15%. In operational terms, the Basel-based company earned just under $4.7 billion (+38%) in the first quarter. The bottom line was a consolidated profit of $3.6 billion after $2.7 billion in the same period of the previous year. According to the press release, the increase was primarily due to the higher operating result. + US tariffs pressure Swiss pharma powerhouse For analysts, however, the core operating profit adjusted for various factors ...
